Our Ta:RNATM platform destroys tumors through a unique multi-modal approach, selectively harnessing the protective power of the body’s antiviral defences.


Our cancer-fighting Ta:RNATM platform uses double-stranded RNA which is protected and guided within a nanoparticle structure to selectively trigger the destruction of cancers. The Ta:RNATM platform can be targeted to a wide range of solid tumours over-expressing specific receptors.


By mimicking natural processes, Ta:RNATM drives a potent combination of apoptosis and immune activation to target heterogeneous tumors. This novel approach has the potential to transform outcomes for cancer patients, whether used alone or in combination with existing treatments.